Nanhua Biotech announced that the 13th meeting of the 12th board of directors of the company reviewed and passed a number of proposals. It is agreed that the company and its subsidiaries within the scope of the merger will use idle capital with an amount not exceeding RMB 300 million to carry out entrusted financial management business. The investment types are low-risk bank short-term wealth management products and fixed income trust products. The amounts are valid for 12 months from the date of review and approval by the shareholders' meeting, and can be used on a rolling basis. At the same time, it was agreed that the total application amount of the company and its holding subsidiaries and subsidiary companies within the scope of the consolidated statement would not exceed RMB 400 million for a comprehensive credit line. In addition, the board of directors agreed to nominate Zhang Liang as a non-independent director candidate for the 12th board of directors, renew the appointment of CIA Zhonghuan Certified Public Accountants as the 2026 auditor, and is scheduled to hold the second Extraordinary General Meeting of Shareholders in 2026 on November 23, 2026.

Nanhua Biotech announced that the 13th meeting of the 12th board of directors of the company reviewed and passed a number of proposals. It is agreed that the company and its subsidiaries within the scope of the merger will use idle capital with an amount not exceeding RMB 300 million to carry out entrusted financial management business. The investment types are low-risk bank short-term wealth management products and fixed income trust products. The amounts are valid for 12 months from the date of review and approval by the shareholders' meeting, and can be used on a rolling basis. At the same time, it was agreed that the total application amount of the company and its holding subsidiaries and subsidiary companies within the scope of the consolidated statement would not exceed RMB 400 million for a comprehensive credit line. In addition, the board of directors agreed to nominate Zhang Liang as a non-independent director candidate for the 12th board of directors, renew the appointment of CIA Zhonghuan Certified Public Accountants as the 2026 auditor, and is scheduled to hold the second Extraordinary General Meeting of Shareholders in 2026 on November 23, 2026.